Lawrence I. Karsh, MD, FACS, discusses the use of SpaceOAR Hydrogel to reduce risk of rectal complications and improve quality of life (QOL) outcomes when treating prostate cancer with radiation therapy. He summarizes supporting clinical evidence, describes the physical application of the gel, and lists players currently offering coverage for the procedure.Read More
Lawrence Karsh, MD, FACS
The Urology Center of Colorado
Dr. Karsh has practiced Urology in Denver since 1984 and was board Certified in 1986, completing the most recent recertification in 2013. He graduated from the Chicago Medical School and completed his General Surgical training at The University of Colorado Health Sciences Center under Dr. Thomas Starzl. He completed his Urology residency at Brigham and Women's Hospital/Harvard Medical School under Dr. Ruben Gittes.[su_spacer] Dr. Karsh is a co-founder of The Urology Center of Colorado where he serves as an attending Urologist and Director of Research. He is a principal investigator with an experience of more than 200 clinical trials. He is a Certified Principal Investigator, certified by the Association of Clinical Research Professionals (ACRP.) Dr. Karsh has authored a number of peer-reviewed publications and serves on the editorial boards for "Urologists in Cancer Care" and "Bladder Cancer." He is an active member of the AUA, SUO,ASCO, as well as SWOG. He serves on the bladder cancer subcommittee for the SUO Clinical Trials Consortium.[su_spacer] Dr. Karsh is also a member of the Denver Academy of Surgeons. Dr. Karsh serves as an advisor and consultant to the pharmaceutical industry, participating in drug development and research protocols. He educates physicians across the country about newly approved therapies.
Articles by Lawrence Karsh, MD, FACS
Posted by Lawrence Karsh, MD, FACS | Apr 2018
Lawrence Karsh, MD, FACS, argues that agonists are effective, sustainable androgen deprivation therapies (ADT) for treating prostate cancer, and claims that agonists present a high cardiovascular (CV) risk could be due to selection bias in trials. Conversely, Thomas Keane, MD, argues that patients treated with antagonists have lower CV risk and are more responsive to ADT than those treated with agonists.Read More
Ask the Expert: What Are Some of the Challenges for Urologists Treating Metastatic Castrate Resistant Prostate Cancer Patients?
Posted by Lawrence Karsh, MD, FACS | Nov 2017
Lawrence Karsh, MD, The Urology Center of Colorado, Denver, Colorado, discusses what some of the...Read More
Ask the Expert: How Do Urologists and Medical Oncologists Differ in Their Approach to Prostate Cancer?
Posted by Lawrence Karsh, MD, FACS | Oct 2017
Lawrence Karsh, MD, The Urology Center of Colorado, Denver, Colorado, discusses how urologists and...Read More
Posted by Lawrence Karsh, MD, FACS | Apr 2017
Dr. Lawrence I. Karsh presented “The Benefits and Challenges (Present and Future) for the...Read More